Our look is new. Our purpose is the same. Learn more about our brand evolution.
From Acceleron’s press release Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that treatment […]
From PRWeb The FSHD Society announced today that it has signed a memorandum of understanding to enter into a three-year agreement to enable the expansion of the international facioscapulohumeral muscular dystrophy […]
From the FSHD Society’s webinar series on facioscapulohumeral muscular dystrophy. Charis Himeda, PhD, of the University of Nevada Reno, discusses her groundbreaking work showing how CRISPR “gene editing” technology can […]
August 19, 2019 at 7:00 AM EDT From Fulcrum press release.  PDF Version CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving […]
How DUX4 could cause FSHD without actually being there BY AMANDA HILL, HIGHLANDS RANCH, COLORADO In the FSHD research field, there is an emerging idea that the damage caused by […]
